\BOOKMARK [1][-]{section.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.2}{Methods}{}% 2
\BOOKMARK [2][-]{subsection.2.1}{Dataset}{section.2}% 3
\BOOKMARK [2][-]{subsection.2.2}{Variant classification occurrence probability}{section.2}% 4
\BOOKMARK [2][-]{subsection.2.3}{Integrating observed true positives and unobserved false negatives into a single, actionable conclusion}{section.2}% 5
\BOOKMARK [2][-]{subsection.2.4}{Validation of autosomal dominant estimates using NFKB1}{section.2}% 6
\BOOKMARK [2][-]{subsection.2.5}{Validation study for autosomal recessive CF using CFTR}{section.2}% 7
\BOOKMARK [2][-]{subsection.2.6}{Validation of SCID-specific estimates using PIDâ€“SCID genes}{section.2}% 8
\BOOKMARK [2][-]{subsection.2.7}{Protein network and genetic constraint interpretation}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.8}{Gene set enrichment test}{section.2}% 10
\BOOKMARK [2][-]{subsection.2.9}{Deriving novel PID classifications by genetic PPI and clinical features}{section.2}% 11
\BOOKMARK [2][-]{subsection.2.10}{Probability of observing AlphaMissense pathogenicity}{section.2}% 12
\BOOKMARK [2][-]{subsection.2.11}{Probability model definitions}{section.2}% 13
\BOOKMARK [1][-]{section.3}{Results}{}% 14
\BOOKMARK [2][-]{subsection.3.1}{Occurrence probability across disease genes}{section.3}% 15
\BOOKMARK [2][-]{subsection.3.2}{Integrating observed true positives and unobserved false negatives into a single, actionable conclusion}{section.3}% 16
\BOOKMARK [2][-]{subsection.3.3}{Scenario one - simple diagnosis}{section.3}% 17
\BOOKMARK [2][-]{subsection.3.4}{Scenario two - complex diagnosis}{section.3}% 18
\BOOKMARK [2][-]{subsection.3.5}{Scenario three - currently impossible diagnosis}{section.3}% 19
\BOOKMARK [2][-]{subsection.3.6}{Validation studies}{section.3}% 20
\BOOKMARK [2][-]{subsection.3.7}{Genetic constraint in high-impact protein networks}{section.3}% 21
\BOOKMARK [2][-]{subsection.3.8}{New insight from functional enrichment}{section.3}% 22
\BOOKMARK [2][-]{subsection.3.9}{Genome-wide gene distribution and linkage disequilibrium}{section.3}% 23
\BOOKMARK [2][-]{subsection.3.10}{Novel PID classifications derived from genetic PPI and clinical features}{section.3}% 24
\BOOKMARK [2][-]{subsection.3.11}{Probability of observing AlphaMissense pathogenicity}{section.3}% 25
\BOOKMARK [2][-]{subsection.3.12}{Integration of variant probabilities into IEI genetics data}{section.3}% 26
\BOOKMARK [1][-]{section.4}{Discussion}{}% 27
\BOOKMARK [1][-]{section.5}{Conclusion}{}% 28
\BOOKMARK [1][-]{section.6}{Supplemental}{}% 29
\BOOKMARK [2][-]{subsection.6.1}{Variant class occurrence probability}{section.6}% 30
\BOOKMARK [2][-]{subsection.6.2}{Integrating observed true positives and unobserved false negatives into a single, actionable conclusion}{section.6}% 31
\BOOKMARK [2][-]{subsection.6.3}{Validation studies}{section.6}% 32
\BOOKMARK [2][-]{subsection.6.4}{Genetic constraint in high-impact protein networks}{section.6}% 33
\BOOKMARK [2][-]{subsection.6.5}{Novel PID classifications derived from genetic PPI and clinical features}{section.6}% 34
\BOOKMARK [2][-]{subsection.6.6}{Probability of observing AlphaMissense pathogenicity}{section.6}% 35
